Bioventus Inc. BVS
Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026
Bioventus Inc. (BVS) is a healthcare company listed in the US with a market value of about $730M. In the twelve months to September 26, 2026 it had revenue of $586M and net income of $57M, a net margin of 9.8%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is value (3/5); the weakest is future growth (1/5).
Key numbers: a P/E of 13.3, a price to free cash flow of 8.6, 5-year revenue growth of 12% a year, a 5-year average ROIC of -4%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 50% below the current price.
About Bioventus
Bioventus is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $340M in 2019 to $568M in 2025, growth of about 8.9% a year. It was profitable in 4 of the last 7 years in our data. Its share count rose by 12% over three years (dilution for shareholders). It spends 2% of revenue on research and development.
Score: 1.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Profit margin improving
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $586M | $568M | $573M | $512M | $512M | $431M | $321M | $340M |
| Net income | $57M | $23M | -$36M | -$156M | -$159M | $19M | $16M | $7M |
| Free cash flow | $85M | $72M | $38M | $8M | -$15M | $9M | $55M | $38M |
| EPS (diluted) | $0.80 | $0.33 | $-0.56 | $-2.49 | $-2.59 | $-0.15 | — | — |
| Net margin | 9.8% | 4.0% | -6.3% | -30.5% | -31.0% | 4.5% | 5.1% | 2.0% |
| ROIC | — | 8.8% | -2.8% | -11.1% | -16.8% | 1.1% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $16.60, 56% above the current price; targets range from $15.00 to $18.00; the consensus rating is “Strong buy”; expected EPS is $0.77 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Bioventus’s P/E ratio?
About 13.3, based on the last twelve months of diluted earnings per share (forward P/E about 12.8).
Is Bioventus stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 50% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Bioventus pay a dividend?
Not currently.
Is Bioventus a good stock to buy?
We do not give buy or sell advice. Bioventus scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.